These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

820 related items for PubMed ID: 24764664

  • 1. Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.
    Feng QY, Wei Y, Chen JW, Chang WJ, Ye LC, Zhu DX, Xu JM.
    World J Gastroenterol; 2014 Apr 21; 20(15):4263-75. PubMed ID: 24764664
    [Abstract] [Full Text] [Related]

  • 2. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
    García-Foncillas J, Díaz-Rubio E.
    Clin Transl Oncol; 2010 Aug 21; 12(8):533-42. PubMed ID: 20709651
    [Abstract] [Full Text] [Related]

  • 3. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
    Chan DLH, Segelov E, Wong RS, Smith A, Herbertson RA, Li BT, Tebbutt N, Price T, Pavlakis N.
    Cochrane Database Syst Rev; 2017 Jun 27; 6(6):CD007047. PubMed ID: 28654140
    [Abstract] [Full Text] [Related]

  • 4. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY.
    J Clin Oncol; 2014 Jul 20; 32(21):2240-7. PubMed ID: 24687833
    [Abstract] [Full Text] [Related]

  • 5. Role of cetuximab in first-line treatment of metastatic colorectal cancer.
    Sotelo MJ, García-Paredes B, Aguado C, Sastre J, Díaz-Rubio E.
    World J Gastroenterol; 2014 Apr 21; 20(15):4208-19. PubMed ID: 24764659
    [Abstract] [Full Text] [Related]

  • 6. No survival benefit from adding cetuximab or panitumumab to oxaliplatin-based chemotherapy in the first-line treatment of metastatic colorectal cancer in KRAS wild type patients: a meta-analysis.
    Zhou SW, Huang YY, Wei Y, Jiang ZM, Zhang YD, Yang Q, Xie DR.
    PLoS One; 2012 Apr 21; 7(11):e50925. PubMed ID: 23226426
    [Abstract] [Full Text] [Related]

  • 7. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D, Li L, Zhang X, Gao G, Shen L, Hu J, Yang M, Liu B, Qian X.
    Medicine (Baltimore); 2018 Mar 21; 97(10):e0097. PubMed ID: 29517682
    [Abstract] [Full Text] [Related]

  • 8. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
    Colucci G, Giuliani F, Garufi C, Mattioli R, Manzione L, Russo A, Lopez M, Parrella P, Tommasi S, Copetti M, Daniele B, Pisconti S, Tuveri G, Silvestris N, Maiello E.
    Oncology; 2010 Mar 21; 79(5-6):415-22. PubMed ID: 21474966
    [Abstract] [Full Text] [Related]

  • 9. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
    Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP, MRC COIN Trial Investigators.
    Lancet; 2011 Jun 18; 377(9783):2103-14. PubMed ID: 21641636
    [Abstract] [Full Text] [Related]

  • 10. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
    Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ.
    N Engl J Med; 2009 Feb 05; 360(6):563-72. PubMed ID: 19196673
    [Abstract] [Full Text] [Related]

  • 11. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J, Punt CJ.
    Clin Ther; 2010 Mar 05; 32(3):437-53. PubMed ID: 20399983
    [Abstract] [Full Text] [Related]

  • 12. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR, Cohn A, Dakhil S, Saleh M, Piperdi B, Cline-Burkhardt M, Tian Y, Go WY.
    Clin Colorectal Cancer; 2015 Jun 05; 14(2):72-80. PubMed ID: 25982297
    [Abstract] [Full Text] [Related]

  • 13. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL, Pavlakis N, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, Segelov E.
    PLoS One; 2015 Jun 05; 10(8):e0135599. PubMed ID: 26275292
    [Abstract] [Full Text] [Related]

  • 14. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.
    Ann Surg; 2010 Feb 05; 251(2):254-60. PubMed ID: 20010090
    [Abstract] [Full Text] [Related]

  • 15. Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.
    Wen F, Tang R, Sang Y, Li M, Hu Q, Du Z, Zhou Y, Zhang P, He X, Li Q.
    Cancer Sci; 2013 Oct 05; 104(10):1330-8. PubMed ID: 23822592
    [Abstract] [Full Text] [Related]

  • 16. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials.
    Sorich MJ, Wiese MD, Rowland A, Kichenadasse G, McKinnon RA, Karapetis CS.
    Ann Oncol; 2015 Jan 05; 26(1):13-21. PubMed ID: 25115304
    [Abstract] [Full Text] [Related]

  • 17. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
    Stintzing S, Miller-Phillips L, Modest DP, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann V, FIRE-3 Investigators.
    Eur J Cancer; 2017 Jul 05; 79():50-60. PubMed ID: 28463756
    [Abstract] [Full Text] [Related]

  • 18. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD.
    N Engl J Med; 2013 Sep 12; 369(11):1023-34. PubMed ID: 24024839
    [Abstract] [Full Text] [Related]

  • 19. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J.
    J Clin Oncol; 2010 Nov 01; 28(31):4697-705. PubMed ID: 20921465
    [Abstract] [Full Text] [Related]

  • 20. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct 01; 19(109):219-24. PubMed ID: 21180382
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.